Telix Pharmaceuticals disclosed in an ASX filing that The Vanguard Group has become a substantial shareholder. The investment firm now holds a 5.217% voting power in the radiopharmaceutical company.
This position corresponds to 17,705,256 ordinary shares. The notice of initial substantial holder status was triggered on June 19, 2026, with the formal disclosure filed on June 25, 2026.
Vanguard’s entry represents a significant institutional endorsement of Telix's strategy and product pipeline. Such investments often attract further market interest and serve as positive long-term indicators for investors.